(Q34229075)

31 July 2017

1 reference

title

Osteoarthritis management: the role of cyclooxygenase-2-selective inhibitors (English)

1 reference

31 July 2017

1 reference

Schnitzer TJ

1

1 reference

31 July 2017

publication date

1 March 2001

1 reference

31 July 2017

published in

Clinical Therapeutics

1 reference

31 July 2017

volume

23

1 reference

31 July 2017

issue

3

1 reference

31 July 2017

page(s)

313-326; discussion 311-2

1 reference

Review article: COX-II inhibitors--a new generation of safer NSAIDs?

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980041-2

7 January 2021

Cyclooxygenases 1 and 2

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980041-2

7 January 2021

A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980041-2

7 January 2021

Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980041-2

7 January 2021

Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980041-2

7 January 2021

The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980041-2

7 January 2021

Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980041-2

7 January 2021

Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980041-2

7 January 2021

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980041-2

7 January 2021

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980041-2

7 January 2021

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980041-2

7 January 2021

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980041-2

7 January 2021

Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980041-2

7 January 2021

Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980041-2

7 January 2021

Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980041-2

7 January 2021

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980041-2

7 January 2021

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980041-2

7 January 2021

Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980041-2

7 January 2021

Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980041-2

7 January 2021

Nonsteroidal anti-inflammatory drugs: effects on kidney function

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980041-2

7 January 2021

Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980041-2

7 January 2021

Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980041-2

7 January 2021

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980041-2

7 January 2021

COX-1-sparing NSAIDs--is the enthusiasm justified?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980041-2

7 January 2021

10.1016/S0149-2918(01)80041-2

Identifiers

DOI

1 reference

31 July 2017

1 reference